Skip to main content
Log in

Diagnosis and pathogenesis of CNS lupus

Rheumatology International Aims and scope Submit manuscript

Summary

The central nervous system (CNS) is clinically involved in approximately 40% of all systemic lupus erythematosis (SLE) patients. Minor psychiatric symptoms and abnormalities on neuropsychological testing are being detected with increasing frequency. This review summarizes current thinking concerning the diagnosis and pathogenesis of CNS lupus. The main symptoms of CNS lupus can be diffuse (generalized seizures, psychosis) or focal (stroke, peripheral neuropathies). Neuropsychiatric symptoms often occur in the first year of SLE, but are rarely the presenting symptoms of the disease. In studies on the pathology of CNS lupus, vasculopathy, infarcts and haemorrhages are often observed, whereas vasculitis is rare. Endocardial lesions and mural thrombi have also been reported in 33–50% of CNS lupus patients. In fliagnostic imaging of the CNS, magnetic resonance imaging (MRI) scans often provide evidence for edema or small infarcts, both in focal and diffuse CNS lupus, whereas computerized tomography (CT) scans only show gross abnormalitites. The first reports on position emission tomography (PET) scans in CNS lupus patients show decreased glucose uptake in the brain. The cerebral blood flow decreases during active diffuse and focal CNS lupus. The blood-brain barrier is somewhat more frequently impaired in diffuse CNS lupus. Intrathecal IgG and IgM production is observed in 25–66% of all CNS lupus patient. Various specificities of autoantibodies have been observed in CNS lupus. Of these, anticardiolipin (ACA) antibodies show a well-documented association with focal involvement of the CNS in SLE. These antibodies could cause thrombosis by interfering with the protein C pathway of fibrinolysis. In addition, they are associated with endocardial and valvular heart disease, which is often observed in SLE and which could cause ombolism. The relation between ACA and diffuse CNS lupus is not yet clear. Low-avidity anti-DNA antibodies are also found in CNS lupus, possibly because of their fross-reaction with cardiolipin. Antineuronal antibodies and lymphocytotoxic antibodies have been associated with diffuse CNS lupus and abnormalities on neuropsychological testing. However, the population of these antibodies is rather heterogeneous and it has not been possible to assess a common target antigen. Therefore, it is still obscure whether there is also a second immune-mediated mechanism responsible for the development of the diffuse form of CNS lupus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Harris EN, Hughes GRV (1985) Cerebral disease in systemic lupus erythematosus. Springer Semin Immunopathol 8:251–266

    Google Scholar 

  2. Adelman DC, Saltiel E, Klinenberg JR (1986) The neuropsychiatric manifestations of systemic lupus erythematosus: an overview. Semin Arthritis Rheum 15:185–199

    Google Scholar 

  3. Bluestein HG (1987) Neuropsychiatric disorders in systemic lupus erythematosus. In: Lahita RG (ed) Systemic lupus erythematosus. Wiley, New York, pp 593–614

    Google Scholar 

  4. Swaak AJG (1986) Central nervous system involvement in systemic lupus erythematosus. Neth J Med 29:221–229

    Google Scholar 

  5. Futrell N, Millikan C (1989) Frequency, etiology, and prevention of stroke in patients with systemic lupus erythematosus. Stroke 20:583–591

    Google Scholar 

  6. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB (1976) Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum and relationship to other features of the disease. Medicine 55:323–339

    Google Scholar 

  7. Brandt KD, Lessell S (1978) Migrainous phenomena in systemic lupus erythematosus. Arthritis Rheum 21:7–16

    Google Scholar 

  8. Anzola GP, Dalla Volta G, Balestrieri G (1988) Headache in patients with systemic lupus erythematosus: clinical and telethermographic findings. Arch Neurol 45:1061–1062

    Google Scholar 

  9. Dubois EL, Tuffanelli DL (1964) Clinical manifestations of systemic lupus erythematosus. JAMA 190:104–111

    Google Scholar 

  10. O'Connor J, Musher DM (1966) Central nervous system involvement in systemic lupus erythematosus. Arch Neurol 14:157–164

    Google Scholar 

  11. Estes D, Christian CL (1971) The natural history of systemic lupus erythematosus by prospective analysis. Medicine 50:85–95

    Google Scholar 

  12. Gibson T, Myers AR (1976) Nervous system involvement in systemic lupus erythematosus. Ann Rheum Dis 35:198–206

    Google Scholar 

  13. Grigor R, Edmonds J, Lewkonia R, Bresnihan B, Hughes GRV (1978) Systemic lupus erythematosus. A prospective analysis. Ann Rheum Dis 37:121–128

    Google Scholar 

  14. How A, Dent PB, Liao S, Denburg JA (1985) Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 28:789–795

    Google Scholar 

  15. Hochberg MC, Boyd RE, Ahearn JM, Arnett FC, Bias WB, Provost TT, Stevens MB (1985) Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 64:285–295

    Google Scholar 

  16. Denburg JA, Carbotte RM, Denburg SD (1987) Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurology 37:464–467

    Google Scholar 

  17. Johnson RT, Richardson EP (1968) The neurological manifestations of systemic lupus erythematosus. A clinico-pathological study of 24 cases and a review of the literature. Medicine 47:337–369

    Google Scholar 

  18. Ellis SG, Verity MA (1979) Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955–1977. Semin Arthritis Rheum 8:212–221

    Google Scholar 

  19. Devinsky OD, Petito CK, Alonso DR (1988) Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli and thrombotic thrombocytopenic purpura. Ann Neurol 23:380–384

    Google Scholar 

  20. Perry SW (1987) Psychiatric aspects of systemic lupus erythematosus. In: Lahita RG (ed) Systemic lupus erythematosus. Wiley, New York, pp 821–846

    Google Scholar 

  21. Bambery P, Malhotra S, Kaur U, Chadda R, Deodhar SD (1987) Anorexia nervosa in a patient with systemic lupus erythematosus. Rheumatol Int 7:177–179

    Google Scholar 

  22. MacNeill A, Grennan DM, Ward D (1976) Psychiatric problems in systemic lupus erythematosus. Br J Psychiatry 128:442–445

    Google Scholar 

  23. Hirohata S, Hirose S, Miyamoto T (1985) Cerebrospinal fluid IgM, IgA and IgG indexes in systemic lupus erythematosus. Arch Intern Med 145:1843–1846

    Google Scholar 

  24. Kelly MC, Denburg JA (1987) Cerebrospinal fluid immunoglobulins and neuronal antibodies in neuropsychiatric systemic lupus erythematosus and related conditions. J Rheumatol 14:740–744

    Google Scholar 

  25. Hirohata S, Miyamoto T (1990) Elevated leves of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 33:644–649

    Google Scholar 

  26. Quismorio FP, Friou GJ (1972) Antibodies reactive with neurons in SLE patients with neuropsychiatric manifestations. Int Arch Allergy 43:740–748

    Google Scholar 

  27. Bluestein HG, Zvaifler NJ (1976) Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest 57:509–516

    Google Scholar 

  28. Bluestein HG (1979) Heterogeneous neurocytotoxic antibodies in systemic lupus erythematosus. Clin Exp Immunol 35:210–217

    Google Scholar 

  29. Bresnihan B, Hohmeister R, Cutting J, Travers RL, Waldburger M, Black C, Jones T, Hughes GRV (1979) The neuropsychiatric disorder in systemic lupus erythematosus: evidence for both vascular and immune mechanisms. Ann Rheum Dis 38:301–306

    Google Scholar 

  30. Wilson HA, Winfield JB, Lahita RG, Koffler D (1979) Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum 22:458–462

    Google Scholar 

  31. Bluestein HG, Williams GW, Steinberg AD (1981) Cerebrospinal fluid antibodies to neuronal cells: association with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 70:240–246

    Google Scholar 

  32. Pussell BA, Blyth F, Charlesworth JA (1982) Failure to detect brain reactivity of lymphocytotoxins in cerebral lupus. Clin Exp Immunol 47:133–137

    Google Scholar 

  33. Hanly JG, Behmann S, Denburg SD, Carbotte RM, Denburg JA (1989) The association between sequential changes in serum antineuronal antibodies and neuropsychiatric systemic lupus erythematosus. Postgrad Med J 65:622–627

    Google Scholar 

  34. Pischel KD, Bluestein HG, Woods VL Jr (1986) Very late activation antigens are human leukocyte-neuron cross-reactive cell surface antigens. J Exp Med 164:393–406

    Google Scholar 

  35. Woods VL Jr, Pischel KD, Avery ED, Bluestein HG (1989) Antigenic polymorphism of human very late activation protein-2 (platelet glycoprotein Ia-IIa). J Clin Invest 83:978–985

    Google Scholar 

  36. Hanly JG, Rajaraman S, Behmann S, Denburg JA (1988) A novel neuronal antigen identified by sera from patients with systemic lupus erythematosus. Arthritis Rheum 31:1492–1499

    Google Scholar 

  37. Smeenk R, Rooyen Avan, Swaak AJG (1988) dissociation studies of DNA/anti-DNA complexes in relation to anti-DNA avidity. J Immunol Methods 109:27–35

    Google Scholar 

  38. Nossent JC, Huysen V, Smeenk RJT, Swaak AJG (1989) Low avidity antibodies to dsDNA in SLE: a longitudinal study of their clinical significance. Ann Rheum Dis 48:677–682

    Google Scholar 

  39. Nossent JC, Huysen V, Smeenk RJT, Swaak AJG (1989) Low avidity antibodies to dsDNA as a diagnostic tool. Ann Rheum Dis 48:748–752

    Google Scholar 

  40. Smeenk RJT, Lucassen WAM, Swaak AJG (1987) Is anticardiolipin activity a crossreaction of anti-DNA or a separate entity? Arthritis Rheum 30:607–617

    Google Scholar 

  41. Robbins ML, Kornguth SE, Bell CL, Kalinke T, England D, Turski P, Graziano FM (1988) Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 31:623–628

    Google Scholar 

  42. Bonfa E, Golombek SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, Elkon KB (1987) Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 317:265–271

    Google Scholar 

  43. Golombek SJ, Graus F, Elkon KB (1986) Autoantibodies in the cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Rheum 29:1090–1097

    Google Scholar 

  44. Asero R, Agostino PD, Bertetti E, Origgi L, Riboldi P (1988) Clinical findings in patients with SLE whose sera contain antibodies to ribosomal ribonucleoprotein. Immunol Lett 18:1–4

    Google Scholar 

  45. Van Dam AP, Nossent JC, De Jong J, Meilof JF, Ter Borg EJ, Swaak AJG, Smeenk RJT (1990) Diagnostic value of antibodies against ribosomal phosphoproteins. A transversal and longitudinal study. J Rheumatol in press

  46. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet II:1211–1214

    Google Scholar 

  47. Harris EN (1990) Antiphospholipid antibodies. Br J Haematol 74:1–9

    Google Scholar 

  48. Levine SR, Welch KMA (1987) The spectrum of neurologic disease associated with antiphospholipid antibodies. Lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 44:876–883

    Google Scholar 

  49. Harris EN, Gharavi AE, Patel SP, Hughes GRV (1987) Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 april 1986. Clin Exp Immunol 68:215–222

    Google Scholar 

  50. Pengo V, Thiagarajan P, Shapiro S, Heine MJ (1987) Immunological specificity and mechanism of action of IgG lupus anticoagulants. Blood 70:69–76

    Google Scholar 

  51. Ichikawa K, Shimada K, Nawata Y, Ishii T, Tomioka H, Yoshida S, Koike T (1988) Monoclonal hybridoma anti-cardiolipin antibodies from SLE mice. Clin Exp Immunol 74:110–114

    Google Scholar 

  52. Derksen RHWM, Hasselaar P, Blokzijl L, Gmelig-Meyling FHJ, Groot PG de (1988) Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 47:364–371

    Google Scholar 

  53. McNeil HP, Chesterman CN, Krilis SA (1989) Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 73:506–513

    Google Scholar 

  54. Mackworth-Young C (1990) Antiphospholipid antibodies: More than just a disease marker. Immunol Today 11:60–64

    Google Scholar 

  55. Hart RG, Miller VT, Coull BM, Bril V (1984) Cerebral infarction associated with lupus anticoagulant-preliminary report. Stroke 15:114–118

    Google Scholar 

  56. Harris EN, Chang JKH, Asherson RA, Aber VR, Gharavi AE, Hughes GRV (1986) Thrombosis, recurrent fetal loss and thrombocytopenia. Predictive value of the anticardiolipin test. Arch Intern Med 146:2153–2156

    Google Scholar 

  57. Asherson RA, Khamashta MA, Gil A, Vazquez J-J, Chan O, Baguley E, Hughes GRV (1989) Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am J Med 86:391–399

    Google Scholar 

  58. Levine SR, Welch KMA (1987) Cerebrovascular ischemia associated with lupus anticoagulant. Stroke 18:257–263

    Google Scholar 

  59. Levine SR, Kim S, Deegan MJ, Welch KMA (1987) Ischemic stroke associated with anticardiolipin antibodies. Stroke 18:1101–1106

    Google Scholar 

  60. Derksen RHWM, Bouma BN, Kater L (1987) The prevalence and clinical associations of the lupus anticoagulant in systemic lupus erythematosus. Scand J Rheumatol 16:185–192

    Google Scholar 

  61. Kushner M, Simonian N (1989) Lupus anticoagulants, anticardiolipin antibodies and cerebral ischemia. Stroke 20:225–229

    Google Scholar 

  62. McHugh NJ, Maymo J, Skinner RP, James I, Maddison PJ (1988) Anticardiolipin antibodies, livedo reticularis, and major cerebrovascular and renal disease in systemic lupus erythematosus. Ann Rheum Dis 47:110–115

    Google Scholar 

  63. Harris EN, Asherson RA, Gharavi AE, Morgan SH, Derue G, Hughes GRV (1985) Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibodies. Br J Haematol 59:227–230

    Google Scholar 

  64. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero J, Outt HH, Harris EN, Vilardell-Torres M, Hughes GRV (1989) The “primary” antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore) 68:366–374

    Google Scholar 

  65. Hughes GRV, Harris EN, Gharavi AE (1986) The anticardiolipin syndrome. J Rheumatol 13:486–489

    Google Scholar 

  66. Khamashta MA, Gil A, Anciones B, Lavilla P, Valencia ME, Pintado V, Vazquez JJ (1988) Chorea in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 47:681–683

    Google Scholar 

  67. Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN, Hughes GRV (1987) Recurrent stroke and multiinfarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis 46:605–611

    Google Scholar 

  68. Coull BM, Bourdette DN, Goodnight SH Jr, Briley DP, Hart R (1987) Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke 18:1107–1112

    Google Scholar 

  69. Lavalle C, Pizarro S, Drenkard C, Sánchez-Guerrero J, Alarcón-Segovia D (1990) Transverse myelitis. A manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol 17:34–37

    Google Scholar 

  70. Hogan MJ, Brunet DG, Ford MP, Lillicrap D (1988) Lupus anticoagulant, antiphospholipid antibodies and migraine. Can J Neurol Sci 15:420–425

    Google Scholar 

  71. Drew P, Asherson RA, Zuk RJ, Goodwin FJ, Hughes GRV (1987) Aortic occlusion in systemic lupus erythematosus associated with antiphospholipid antibodies. Ann Rheum Dis 46:612–616

    Google Scholar 

  72. Ford PM, Ford SE, Lillicrap DP (1988) Association of lupus anticoagulant with severe valvular heart disease in systemic lupus erythematosus. J Rheumatol 15:597–600

    Google Scholar 

  73. Anderson D, Bell D, Lodge R, Grant E (1987) Recurrent cerebral ischemia and mitral valve vegetation in a patient with antiphospholipid antibodies. J Rheumatol 14:839–841

    Google Scholar 

  74. Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD (1989) Aortic insuffiency und mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 86:407–412

    Google Scholar 

  75. Manoussakis MN, Tzioufas AG, Silis MP, Pange PJE, Goudevenos J, Moutsopoulos HM (1987) High prevalence of anticardiolipin and other autoantibodies in a healthy elderly population. Clin Exp Immunol 69:557–565

    Google Scholar 

  76. Mackworth-Young CG, Chan J, Harris EN, Walport MJ, Bernstein R, Batchelor R, Hughes GRV, Gharavi AE (1987) High incidence of anticardiolipin antibodies in relatives of patients with systemic lupus erythematosus. J Rheumatol 14:723–726

    Google Scholar 

  77. Fort JG, Cowchock FS, Abruzzo JL, Smith JB (1987) Anticardiolipin antibodies in patients with rheumatic diseases. Arthritis Rheum 30:752–760

    Google Scholar 

  78. Sturfelt G, Nived O, Norberg R, Thorstensson R, Krook K (1987) Anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 30:382–388

    Google Scholar 

  79. Corvetta A, Deicher H, Lang B, Peter HH, Robin-Winn M, Roter E, Schendel D, Stannat S, Hartung K (1990) Anti-cardiolipin antibodies and related syndrome in systemic lupus erythematosus: a collaborative study of 334 patients. Clin Exp Rheumatol 8:212 (abstr)

    Google Scholar 

  80. Love PE, Santoro SA (1990) Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 112:682–698

    Google Scholar 

  81. Petri M, Rheinschmidt M, Whiting-O'Keefe, Hellmann D, Corash L (1987) The frequency of lupus anticoagulant in systemic lupus erythematosus. Ann Intern Med 106:524–531

    Google Scholar 

  82. Derksen RWHM, Biesma D, Bouma BN, Gmelig Meyling FHJ, Kater L (1986) Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum 29:1295–1296

    Google Scholar 

  83. Out HJ, de Groot PG, Hasselaar P, van Vliet M, Derksen RHWM (1989) Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 48:1023–1028

    Google Scholar 

  84. Swaak AJG, Aarden LA, Statius van Eps LW, Feltkamp TEW (1979) Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 22:226–235

    Google Scholar 

  85. Swaak AJG, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45:359–366

    Google Scholar 

  86. Ishii Y, Nagasawa K, Mayumi T, Niho Y (1990) Clinical importance of persistence of anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis 49:387–390

    Google Scholar 

  87. Endo T, Scott DD, Steward SS, Kundu SK, Marcus MD (1984) Antibodies to glycosphingolipids in patients with multiple sclerosis and CNS. J Immunol 132:1793–1798

    Google Scholar 

  88. Ader R, Cohen N (1982) Behaviorally conditioned immuno-suppression and murine systemic lupus erythematosus. Science 215:1534–1536

    Google Scholar 

  89. Carreras LO, Vermylen JG (1982) ‘Lupus’ anticoagulant and thrombosis: possible role of inhibition of prostacyclin formation. Thromb Haemost 48:38–40

    Google Scholar 

  90. Hasselaar P, Derksen RHWM, Blokzijl L, Groot PG de (1988) Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial and platelet prostanoid synthesis. Thromb Haemost 59:80–85

    Google Scholar 

  91. Marciniak E, Romond EH (1989) Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus acticoagulant. Blood 74:2426–2432

    Google Scholar 

  92. Amer L, Kisiel W, Searles RP, Williams RC Jr (1990) Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res 57:247–258

    Google Scholar 

  93. Khamashta MA, Cervera R, Asherson RA, Font J, Gil A, Coltart DJ, Vázquez JJ, Par' C, Ingelmo M, Oliver J, Hughes GRV (1990) Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335:1541–1544

    Google Scholar 

  94. Rauch J, Meng Q-H, Tannenbaum H (1987) Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies. J Immunol 139:2598–2604

    Google Scholar 

  95. Damasio H, Beck D (1978) Migraine, thrombocytopenia and serotonin metabolism. Lancet I:240–242

    Google Scholar 

  96. Schrieber L, McCredie M, Tugwell P, Brooks PM (1988) An evaluation on the role of laboratory investigations in establishing a diagnosis of central nervous system lupus. Br J Rheumatol 27:138–142

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Dam, A.P. Diagnosis and pathogenesis of CNS lupus. Rheumatol Int 11, 1–11 (1991). https://doi.org/10.1007/BF00290244

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00290244

Key words

Navigation